Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
83 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Bronchiectasis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Bronchiectasis - Pipeline Review, H2 2014', provides an overview of the Bronchiectasis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Bronchiectasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bronchiectasis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Bronchiectasis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Bronchiectasis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Bronchiectasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Bronchiectasis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Bronchiectasis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Bronchiectasis Overview 8 Therapeutics Development 9 Pipeline Products for Bronchiectasis - Overview 9 Pipeline Products for Bronchiectasis - Comparative Analysis 10 Bronchiectasis - Therapeutics under Development by Companies 11 Bronchiectasis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Unknown Stage Products 16 Bronchiectasis - Products under Development by Companies 17 Bronchiectasis - Companies Involved in Therapeutics Development 19 GlaxoSmithKline plc 19 Grifols, S.A. 20 Chiesi Farmaceutici SpA 21 Zambon Company S.p.A. 22 Bayer AG 23 Kamada Ltd. 24 Nostrum Pharmaceuticals, LLC 25 Pulmatrix, Inc. 26 Edmond Pharma Srl 27 Savara Inc. 28 Clarassance, Inc. 29 Alitair Pharmaceuticals, Inc. 30 Serendex Pharmaceuticals A/S 31 Bronchiectasis - Therapeutics Assessment 32 Assessment by Monotherapy Products 32 Assessment by Target 33 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 ARD-3150 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 ciprofloxacin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 alpha-1-proteinase inhibitor (human) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 BAY-858501 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 vancomycin - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 GSK-2793660 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 erdosteine - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 CG-1011 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules to Inhibit Neutrophil Elastases - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 PUR-0400 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 dapsone - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ALT-07 - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Recombinant Human Follistatin - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 sargramostim - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 ALT-09 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 PUR-1000 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 ZP-044 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Bronchiectasis - Recent Pipeline Updates 66 Bronchiectasis - Dormant Projects 72 Bronchiectasis - Discontinued Products 73 Bronchiectasis - Product Development Milestones 74 Featured News & Press Releases 74 Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 74 Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 75 May 20, 2014: FDA Grants QIDP Designation to Aradigm's Inhaled Antibiotic 76 May 05, 2014: Pulmatrix Presents Preclinical Data on iSPERSE Inhaled Antibiotics at the 2014 Respiratory Drug Delivery Conference 77 Apr 28, 2014: Erdosteine Received Orphan Drug Status by the FDA 77 Jan 07, 2014: Alitair Receives Orphan Drug Designation for Erdosteine in Bronchiectasis 78 Aug 01, 2013: Aradigm Awarded NIH Grant to Investigate the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infections with Pulmaquin and Lipoquin 78 Jun 24, 2013: Kamada Receives Two Key Patents Covering Its New Alpha-1 Antitrypsin Product 79 Apr 24, 2013: Pharmaxis's Phase III Clinical Trial With Bronchitol Fails To Meet Primary Endpoint 80 Mar 08, 2013: Pharmaxis Announces Completion Of Phase III Trial Of Bronchitol For Treatment Of Bronchiectasis 81 Appendix 82 Methodology 82 Coverage 82 Secondary Research 82 Primary Research 82 Expert Panel Validation 82 Contact Us 83 Disclaimer 83
List of Tables Number of Products under Development for Bronchiectasis, H2 2014 9 Number of Products under Development for Bronchiectasis - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Comparative Analysis by Late Stage Development, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Comparative Analysis by Unknown Stage Development, H2 2014 16 Products under Development by Companies, H2 2014 17 Products under Development by Companies, H2 2014 (Contd..1) 18 Bronchiectasis - Pipeline by GlaxoSmithKline plc, H2 2014 19 Bronchiectasis - Pipeline by Grifols, S.A., H2 2014 20 Bronchiectasis - Pipeline by Chiesi Farmaceutici SpA, H2 2014 21 Bronchiectasis - Pipeline by Zambon Company S.p.A., H2 2014 22 Bronchiectasis - Pipeline by Bayer AG, H2 2014 23 Bronchiectasis - Pipeline by Kamada Ltd., H2 2014 24 Bronchiectasis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2014 25 Bronchiectasis - Pipeline by Pulmatrix, Inc., H2 2014 26 Bronchiectasis - Pipeline by Edmond Pharma Srl, H2 2014 27 Bronchiectasis - Pipeline by Savara Inc., H2 2014 28 Bronchiectasis - Pipeline by Clarassance, Inc., H2 2014 29 Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H2 2014 30 Bronchiectasis - Pipeline by Serendex Pharmaceuticals A/S, H2 2014 31 Assessment by Monotherapy Products, H2 2014 32 Number of Products by Stage and Target, H2 2014 34 Number of Products by Stage and Mechanism of Action, H2 2014 36 Number of Products by Stage and Route of Administration, H2 2014 38 Number of Products by Stage and Molecule Type, H2 2014 40 Bronchiectasis Therapeutics - Recent Pipeline Updates, H2 2014 66 Bronchiectasis - Dormant Projects, H2 2014 72 Bronchiectasis - Discontinued Products, H2 2014 73
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
